1. Home
  2. BNR vs TLSI Comparison

BNR vs TLSI Comparison

Compare BNR & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$16.20

Market Cap

252.7M

Sector

Health Care

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$4.24

Market Cap

267.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNR
TLSI
Founded
2014
2010
Country
China
United States
Employees
N/A
110
Industry
Medical Specialities
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
252.7M
267.1M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
BNR
TLSI
Price
$16.20
$4.24
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$7.00
AVG Volume (30 Days)
31.2K
190.8K
Earning Date
03-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$111.65
$36.47
Revenue Next Year
N/A
$39.31
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.18
$3.42
52 Week High
$41.72
$7.95

Technical Indicators

Market Signals
Indicator
BNR
TLSI
Relative Strength Index (RSI) 35.63 49.11
Support Level $15.52 $3.79
Resistance Level $23.42 $5.33
Average True Range (ATR) 1.39 0.24
MACD -0.01 0.06
Stochastic Oscillator 11.27 81.82

Price Performance

Historical Comparison
BNR
TLSI

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.

Share on Social Networks: